Blog Archives

Understanding the Value of Medication: Whose job is it?

There has been a lot of discussion about drugs and drug pricing of late, including the idea of value-based purchasing.  One element, though, that hasn’t been getting quite enough attention is just how a patient or a pharmacist or a

Tagged with: , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

Drug Pricing: Where Are We Now?

Back in September, I mused that little was new in the drug pricing debate.  Today, while it is still true that novel solutions are not under discussion, there does seem to be new energy to the debate.  The issue has become

Tagged with: , , , ,
Posted in Health Care Costs, Pharmaceuticals

What’s Old is New Again: Proposals to Rein in Drug Prices are Nothing New

It used to be that Americans would look the other way when it came to drug prices, concluding that the benefit outweighed the costs.  However, with prices continuing their march upward and with more of that price being borne directly

Tagged with: , , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

A Major Loss for Consumers: FDA Proposed Rule on Biosimilar Naming Threatens Savings and Offers No Gain in Safety

This morning’s proposed rule on biosimilar naming marks a major win for PhRMA and BIO and a loss for consumers, not to mention a reversal of FDA policy.  At a time when more than 70% of Americans believe drug companies

Tagged with: , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

True Public Service: A Moment of Appreciation for Frances Oldham Kelsey and Dedicated Countless Others at the FDA

Earlier this month Dr. Frances Oldham Kelsey passed away.  Although not a household name today, she became that rare thing: a civil servant who was not anonymous.  To the contrary, for a time, Dr. Kelsey was recognized by the public

Tagged with: , , , , , ,
Posted in Pharmaceuticals

Are We Reaching a Tipping Point on Drug Prices?

Is it just me, or does it seem like there is a groundswell of concern regarding drug prices?  Is it possible that we are reaching a tipping point and the U.S. may finally act to curb abuses? Just yesterday, Senator

Tagged with: , , , , , , ,
Posted in Pharmaceuticals

Investments Needed No Matter Which Way You Turn: The Hepatitis C Dilemma

A lot of attention has been paid to Sovaldi and Harvoni this last year, with perhaps more attention given to their remarkable price tags than to their remarkable efficacy.  This is somewhat understandable as the twelve-week course of treatment of

Tagged with: , , , , ,
Posted in Medicaid, Pharmaceuticals

More Questions Than Answers: The Biosimilar Pathway

It’s not that often in the legal world that truly novel questions are presented, the kind to which lawyers can only offer answers in conjectures and hopes rather than opinions.  Now is such a time as the first biosimilar case

Tagged with: , , ,
Posted in Biosimilars, Pharmaceuticals

Why Should I, A Self-Professed Health Policy Nerd, Care About the Trans-Pacific Partnership (TPP) Trade Agreement?

Trade negotiations are the stuff of legend around here – high stakes politics and international business, all transacted behind closed doors with the strictest of confidentiality measures in place.  That said, I don’t always pay them much attention.  This time

Tagged with: , , ,
Posted in Biosimilars, Pharmaceuticals